| 234.18 -1.32 (-0.56%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 279.14 | 1-year : | 286.13 |
| Resists | First : | 238.99 | Second : | 244.97 |
| Pivot price | 236.9  |
|||
| Supports | First : | 229.3 | Second : | 190.78 |
| MAs | MA(5) : | 235.25 |
MA(20) : | 236.53 |
| MA(100) : | 234.29 |
MA(250) : | 240.06 |
|
| MACD | MACD : | -0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 32.8 |
D(3) : | 33.9 |
| RSI | RSI(14): 46.6 |
|||
| 52-week | High : | 269.51 | Low : | 218.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BDX ] has closed above bottom band by 27.1%. Bollinger Bands are 9.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 237.78 - 238.94 | 238.94 - 240.08 |
| Low: | 230.43 - 231.89 | 231.89 - 233.33 |
| Close: | 231.48 - 233.79 | 233.79 - 236.07 |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Sat, 14 Sep 2024
DekaBank Deutsche Girozentrale Raises Stock Position in Becton, Dickinson and Company (NYSE:BDX) - MarketBeat
Fri, 13 Sep 2024
The Latest Breaking News from Becton, Dickinson, and Company - Inkl
Fri, 13 Sep 2024
Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Forsta AP Fonden - MarketBeat
Fri, 13 Sep 2024
Becton, Dickinson and Company: Future Benefit From GLP-1 Drug Delivery (NYSE:BDX) - Seeking Alpha
Tue, 10 Sep 2024
Is Becton, Dickinson, and Company Stock Underperforming the Nasdaq? - Inkl
Tue, 10 Sep 2024
Here's Why Becton Dickinson (BDX) is a Strong Value Stock - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 289 (M) |
| Shares Float | 288 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 90 (%) |
| Shares Short | 1,980 (K) |
| Shares Short P.Month | 1,980 (K) |
| EPS | 4.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 89.5 |
| Profit Margin | 7.1 % |
| Operating Margin | 15.1 % |
| Return on Assets (ttm) | 3.2 % |
| Return on Equity (ttm) | 5.6 % |
| Qtrly Rev. Growth | 2.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 68.6 |
| EBITDA (p.s.) | 17.67 |
| Qtrly Earnings Growth | 23.5 % |
| Operating Cash Flow | 3,940 (M) |
| Levered Free Cash Flow | 4,430 (M) |
| PE Ratio | 46.92 |
| PEG Ratio | 2 |
| Price to Book value | 2.61 |
| Price to Sales | 3.41 |
| Price to Cash Flow | 17.17 |
| Dividend | 0.94 |
| Forward Dividend | 0 |
| Dividend Yield | 0.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|